The U.S. Food and Drug Administration has approved Eli Lilly’s oral obesity treatment orforglipron, which will be marketed under the brand name Foundayo, marking a significant development in the emerging market for weight-loss pills. The decision positions the drug as a direct competitor to Novo Nordisk’s oral Wegovy, which entered the U.S. market earlier this year.
According to the announcement, Foundayo will be made available through LillyDirect®, with prescriptions accepted immediately and shipments scheduled to begin on April 6. Pricing has been set at $25 per month for patients with commercial insurance coverage, while a self-pay option will cost $149 per month. The company indicated that distribution will later expand to retail pharmacies and telehealth providers.
The approval was granted under the FDA’s Commissioner’s National Priority Voucher Program, an initiative launched in June 2025 to accelerate review timelines for selected therapies. Foundayo was approved 50 days after filing, significantly ahead of its Prescription Drug User Fee Act (PDUFA) date of January 20, 2027.
Foundayo is a once-daily oral medication designed to mimic the GLP-1 hormone, which regulates appetite. This mechanism aligns with other drugs in Lilly’s portfolio, including Mounjaro for diabetes and Zepbound for weight management. Together, these products are projected by Truist Securities to generate up to $101 billion in peak global revenue, based on an estimated eligible population of 17.6 million individuals and a monthly price assumption of $200.
The approval is supported by clinical data from multiple Phase 3 studies. In the ATTAIN-1 trial, the highest tested dose of 36 mg resulted in an average weight reduction of 27.3 pounds over 72 weeks. The drug also demonstrated improvements in cardiometabolic risk factors. Additional findings from the ACHIEVE-3 study showed that Foundayo produced greater weight loss and improved glycemic control compared to oral semaglutide in patients with type 2 diabetes inadequately managed with metformin.
By comparison, Novo Nordisk’s oral Wegovy achieved a mean weight loss of 16.6% in the OASIS 4 trial at a 25 mg dose. While Wegovy recorded a strong market entry, reaching approximately 3,100 patients in its first week, analysts had anticipated increased competition from Lilly’s oral candidate.
Manufacturing differences may also influence market dynamics. Foundayo, as a small molecule, is less complex to produce than peptide-based therapies like oral Wegovy. As Evan Seigerman noted, “A small molecule could be potentially influential in the fight for the oral obesity market.” He made this statement in an August 2025 interview with BioSpace.
The drug’s labeling includes a boxed warning regarding the risk of thyroid C-cell tumors. The FDA specified that Foundayo should not be used in patients with a personal or family history of medullary thyroid cancer or in those diagnosed with Multiple Endocrine Neoplasia syndrome type 2.
The approval comes amid an ongoing competitive landscape between Lilly and Novo Nordisk. In the injectable segment, Lilly’s Mounjaro reported $22.965 billion in sales last year, surpassing Novo’s Ozempic, which generated $20.1 billion. The introduction of Foundayo provides Lilly with an additional position in the oral treatment segment, which analysts estimate could account for approximately 20% of the obesity drug market by 2030.
Differences in administration may also affect patient preference. Foundayo can be taken at any time without restrictions, whereas oral Wegovy must be taken in the morning and requires a waiting period before food or other medications.
Following the announcement, Eli Lilly’s shares rose by 4%, while Novo Nordisk’s U.S.-listed shares declined by nearly 2%, reflecting market’s response to the approval.
Impact on the Obesity Drug Market
The approval of Foundayo intensifies competition in the multi-billion-dollar obesity drug market. Analysts expect oral GLP-1 drugs like Foundayo to capture a growing share as demand rises for convenient therapies.
Foundayo is expected to compete directly with established brands while also expanding the overall market by attracting new patients.
Safety and Considerations for Foundayo
Like other GLP-1 therapies, Foundayo may cause side effects such as nausea, gastrointestinal discomfort, and fatigue. Additionally, Foundayo carries warnings related to thyroid tumor risks, consistent with this drug class.
Patients are advised to use Foundayo under medical supervision as part of a broader lifestyle program.
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
